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Abstract
Background: Multimorbidity is increasing in aging populations with a corresponding increase in polypharmacy as well
as inappropriate prescribing. Depending on definitions, 25-50 % of patients aged 75 years or older are exposed to at
least five drugs. Evidence is increasing that polypharmacy, even when guidelines advise the prescribing of each drug
individually, can potentially cause more harm than benefit to older patients, due to factors such as drug-drug and
drug-disease interactions. Several approaches reducing polypharmacy and inappropriate prescribing have been
proposed, but evidence showing a benefit of these measures regarding clinically relevant endpoints is scarce.
There is an urgent need to implement more effective strategies. We therefore set out to develop an evidence-based
electronic decision support (eDS) tool to aid physicians in reducing inappropriate prescribing and test its effectiveness
in a large-scale cluster-randomized controlled trial.
Methods: The “Polypharmacy in chronic diseases–Reduction of Inappropriate Medication and Adverse drug events in
older populations” (PRIMA)-eDS tool is a tool comprising an indication check and recommendations for the reduction
of polypharmacy and inappropriate prescribing based on systematic reviews and guidelines, the European list
of inappropriate medications for older people, the SFINX-database of interactions, the PHARAO-database on
adverse effects, and the RENBASE-database on renal dosing. The tool will be evaluated in a cluster-randomized
controlled trial involving 325 general practitioners (GPs) and around 3500 patients across five study centres in the United
Kingdom, Germany, Austria and Italy. GP practices will be asked to recruit 11 patients aged 75 years or older who are
taking at least eight medications and will be cluster-randomized after completion of patient recruitment. Intervention
GPs will have access to the PRIMA-eDS tool, while control GPs will treat their patients according to current guidelines
(usual care) without access to the PRIMA-eDS tool. After an observation time of 2 years, intervention and control groups
will be compared regarding the primary composite endpoint of first non-elective hospitalization or death.
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Discussion: The principal hypothesis is that reduction of polypharmacy and inappropriate prescribing can improve the
clinical composite outcome of hospitalization or death. A positive result of the trial will contribute substantially to
the improvement of care in multimorbidity. The trial is necessary to investigate not only whether the reduction of
polypharmacy improves outcome, but also whether GPs and patients are willing to follow the recommendations
of the PRIMA-eDS tool.
Trial registration: This trial has been registered with Current Controlled Trials Ltd. on 31 July 2014
(ISRCTN10137559).
Keywords: Polypharmacy, Electronic decision support, Primary care, Multimorbidity, Inappropriate prescribing,
Randomized controlled trial
Background
The prevalence of multimorbidity is substantial and
affects more than half of the population aged 75 years
or older in developed countries [1]. Cardiovascular
disease (including coronary heart disease, cerebrovas-
cular disease and peripheral vascular disease), heart
failure, hypertension, atrial fibrillation, diabetes mellitus
type 2, musculoskeletal pain, chronic obstructive pulmon-
ary disease (COPD), and mental diseases like depression
and dementia most often co-occur, with heart failure
showing the highest rate of comorbidity, being accompan-
ied by an average of 2.9 additional chronic diseases [2]. It
is generally recommended to treat each chronic condition
in accordance with disease-specific guidelines. However,
most clinical practice guidelines do not modify or discuss
the applicability of their recommendations for older pa-
tients with multiple diseases and following all guidelines
for each and every drug a patient is taking will inevitably
lead to polypharmacy [3]. Even though the term “poly-
pharmacy” is frequently used to describe the use of mul-
tiple medications, a clear definition is still lacking. The
variety of definitions reflects the difficulty in setting an ac-
curate cut-off point. According to the medical literature
review of Bushardt et al., the most common cut-off point
is the use of more than five medications [4]. Depending
on definitions and setting, between 25 and 50 % of all pa-
tients age 75 years or older are exposed to five or more
drugs [5–8]. The clinical trial evidence of benefit for most
drugs is based on studies of mostly younger, fitter subjects
with a life expectancy of many years, even though these
drugs are most often prescribed for older patients with
multimorbidity, and the findings of these studies may not
be so applicable due to drug-drug and drug-disease inter-
actions as well as aging processes and a reduced life ex-
pectancy [9, 10].
Polypharmacy is associated with an increased risk for
medication errors [11] and adverse drug events (ADE)
[12, 13] which in turn are frequent causes of hospitaliza-
tion [14]. Various international studies report a hospi-
talization rate due to ADE of between 2.4 and 16.6 %,
depending largely on the age group evaluated [15–17].
Polypharmacy and inappropriate medication have been
shown to contribute substantially to the burden of mor-
bidity, hospitalization and death [18]. Up to 50 % of
ADE and ADE-related hospitalizations are judged to be
preventable by avoiding inappropriate prescribing [19].
Although exact figures are not available for all coun-
tries, it may be assumed that between 60 and 80 % of
all patient prescriptions are initiated by general practi-
tioners (GPs). In Germany, 67.6 % of all prescriptions
covered by statutory public health insurance are attrib-
utable to GPs [20]. Any intervention aimed at the
reduction of polypharmacy will, therefore, be most ef-
fective if targeted at GPs.
A number of diverse approaches to reduce polyphar-
macy and inappropriate prescribing have been proposed,
but no convincing evidence from sufficiently powered
randomized controlled trials exists regarding their prac-
ticality for use in primary care or their impact on clinic-
ally relevant endpoints. There is limited evidence that
the Beers Criteria list of potentially inappropriate medi-
cations (PIM) for older patients has some associations
with adverse outcomes, but this evidence is mostly based
on retrospective cohort studies, and there is no study
showing that avoiding drugs on a PIM list for older pa-
tients like the Beers list will improve outcomes [21].
There is also preliminary evidence that the prudent re-
duction of polypharmacy using the Garfinkel algorithm
may be beneficial to patients, but Garfinkel used a non-
randomized design in his studies [22, 23]. Similarly, it
has been shown that the application of STOPP-criteria is
associated with ADE [24, 25] and a reduction of PIMs
[26], but a randomized controlled trial proving that this
also improves clinical outcome does not exist.
Use of a simple interdisciplinary medication review
has been shown to lead to the reduction of inappropriate
prescribing and costs, but there was no effect on clinic-
ally relevant patient outcomes, possibly due to a lack of
power and insufficient observation time [27].
Some authors suggest a “process of deprescribing,” pri-
oritizing drugs in a patient with polypharmacy according
to each drug’s risk/benefit ratio, but likewise we do not
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have evidence from randomized trials supporting this
strategy [28].
A recently updated Cochrane review concluded that both
the application of the “medication appropriateness index”
(MAI) and the Beers list appeared to improve medication
appropriateness, but effects on outcome were inconsistent,
and the quality of evidence has been graded as low or very
low [29]. Moreover, most of the studies included in the re-
view were carried out in a hospital or nursing home setting.
There is a strong need for improved interventions to
reduce inappropriate prescribing and polypharmacy, es-
pecially in the primary care setting. We therefore set out
to develop an electronic decision support (eDS) tool
based on current best evidence and targeted at the pri-
mary care setting to help GPs identify and reduce in-
appropriate prescribing and polypharmacy in older
patients. The principal intervention will be the recom-
mendation for drug discontinuation or modification by
the “Polypharmacy in chronic diseases Reduction of In-
appropriate Medication and Adverse drug events in older
populations” (PRIMA)-eDS tool (see Methods section for
further description of the tool).
Objectives of the study
Our principal hypothesis is that the reduction of polyphar-
macy and inappropriate prescribing will improve clinical
outcomes for older patients. The primary objective is to
test this hypothesis by the evaluation of the PRIMA-eDS
tool in a multicenter cluster-randomized controlled trial
with the combined primary endpoint of first non-elective
hospital admission or death (see Table 1).
Secondary objectives are to evaluate the effective-
ness of the decision support tool regarding all-cause
mortality and non-elective hospital admission as sin-




The PRIMA-eDS trial is a multicentre cluster-randomized
controlled trial with an observation time of 2 years using
GP practices as clusters of randomization. It will be
conducted at five study centres recruiting GP prac-
tices in their corresponding region/country. The prin-
cipal trial centre and coordinator of the study is the
Institute of General Practice and Family Medicine of
Witten/Herdecke University (Germany). The other
four study centres are the University of Manchester
(United Kingdom), the Rostock University Medical
Centre (Germany), the Paracelsus Medical University
(Austria), and the South Tyrolean Academy of General
Practice (Italy).
Ethics approval
The study has been approved by the five local ethics
committees: 1. Ethikkomission der Universität Witten/
Herdecke, 3 December 2013, ref. 103/2013; 2. NRES
Committee North West Greater Manchester East, 6
June 2014, ref. 14/NW/0197; 3. Ethikkommission für das
Bundesland Salzburg, 15 September 2013, ref. 08.04.2014
(415-E/1509/20-2014); 4. Ethikkommission der Universi-
tätsmedizin Rostock, 3 February 2014, ref. A 2014-0020;
and 5. Comitato etico di Belluno (Azienda ULSS), 19 June
2013, ref. 305388-2.
Setting
The PRIMA-eDS trial will be located in the primary care
setting including community as well as nursing home
resident older patients taking at least eight drugs (active
ingredients with a systemic effect, combination drugs
are counted according to the number of active ingredi-
ents). We chose the inclusion-criterion of at least eight
drugs because the sample size calculation of this trial is
based on the study by Garfinkel where a corresponding
number of drugs was taken by the participants [23].
Table 2 provides a list of the five study centres and their
corresponding settings for recruitment of GP practices.
Recruitment of GP practices and patients
Each study center will inform all GPs of a selected region
or a GP practice network (see Table 2 for details) about
the trial, first in writing, and then followed by a telephone
call, and invite them to participate in the study. After giv-
ing informed consent, GPs are encouraged to identify all
patients of their GP practice eligible to participate from
the electronic health record of the GP practice and check
these for inclusion and exclusion criteria.
Inclusion criteria
 Age 75 years or older
 Intake of at least eight drugs including drugs
prescribed by the GP or any other physician (e.g.,
specialist) and non-prescription drugs (including
PRN (pro re nata) medication)
Table 1 PICO research question of the PRIMA-eDS trial
PICO-Item Research question
P (patients) Patients aged ≥75 years taking ≥8 drugs in
primary care
I (intervention) GPs of enrolled patients with access to the
PRIMA-eDS tool
C (comparison) GPs of enrolled patients without access to the
PRIMA-eDS tool (usual care)
O (outcome) Non-elective hospitalization or death within an
observation time of 2 years
PRIMA-eDS Polypharmacy in chronic diseases - Reduction of Inappropriate
Medication and Adverse drug events in older populations by electronic
Decision Support
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Exclusion criteria
Patients will be excluded if their life expectancy is as-
sumed to be less than 1 year (assumption based on
GP judgment). Other exclusion criteria are ongoing
chemotherapy and/or ongoing therapeutic radiation
for systemic malignant disease, and dementia with in-
ability to provide informed consent. All or a sample
of the eligible patients at the discretion of the GP are
then invited in writing or by personal contact to par-
ticipate in the trial. After giving informed consent in
accordance with the declaration of Helsinki, patients
are continuously included in the study. GPs are
instructed to aim for a minimum of eight and a max-
imum of 15 patients to keep cluster size constant.
The flow of recruitment is depicted in Additional file
1: Figure S1.
Randomization
The unit of randomization will be the GP practice, such
that each participating GP and their patients will be ran-
domized to either have use of the PRIMA-eDS tool
(intervention), or not (control). This avoids any risk of
contamination that would occur if GPs were using the
tool with some of their patients but not others. The
intended GP practice cluster size is around 11 patients
(see sample size calculation). To assure concealment of
allocation, each GP practice reports to the Department
of Medical Informatics, Biometry and Epidemiology,
Ruhr University, Bochum, Germany as soon as patient
recruitment has been completed, and is then cluster-
randomized by computerized sequence generation. Thus,
neither patients nor GPs will know whether they will take
part as an intervention or control cluster at the time of re-
cruitment. To avoid over-representation of a single study
center in the intervention group, randomization will be
stratified by study center.
Blinding
Inherent to the study protocol GPs and patients cannot
be blinded. The analyst will be kept blind to GP practice
allocation.
Intervention
The principal intervention will be the recommendation
for drug discontinuation or modification by the
PRIMA-eDS tool. This is a novel decision support tool
which has been developed by the PRIMA-eDS consor-
tium to make current best evidence regarding drug
treatment of chronic diseases in older patients available
to GPs in daily practice. The tool analyses the patientʼs
diagnoses, current medication, symptoms, biometric
measurements (e.g., body mass index, blood pressure)
and laboratory values, performs an electronic compre-
hensive medication review, and returns recommenda-
tions for drug discontinuation or modification based on
the following components:
 Indication and contraindication check for all
prescribed drugs according to the diagnoses
provided and the officially approved indications by
the European Medicines Agency (EMA)
 Forty rules and recommendations based on
systematic reviews of clinical trial and observational
study evidence on usage of the most commonly
prescribed drugs in older patients [30]
 Ninety-five rules and recommendations taken from
the Evidence-Based Medicine electronic Decision
Support (EBMeDS) database (http://www.ebmeds.
org/web/guest/home). These recommendations in
turn are derived from the NICE-approved Evidence
Based Medicine Guidelines (EBMG; http://www.
duodecim.fi/web/duodecimpublications/ebmg) to
assure regular updating
 RENBASE renal dosing decision support software
(http://www.medbase.fi/en/professionals/renbase)
 Swedish, Finnish, INteraction X-referencing (SFINX)
interaction check decision support software
(www.medbase.fi/en/professionals/sfinx) [31]
 PHARAO decision support software on adverse
drug reactions (http://www.medbase.fi/en/
professionals/pharao)
 Check of drugs listed in the European list of
potentially inappropriate medication for older
patients [32]
Table 2 Study centres and settings of the trial
Study centre Settings for the recruitment of GP practices
University of Witten/Herdecke Network of teaching and research practices of the university; list of all GP practices providing
care for patients with statutory public health insurance in the region of South Eastern
North-Rhine-Westfalia
Rostock University Medical Centre List of all GP practices providing care for patients with statutory public health insurance in the
region of Mecklenburg-Western Pomerania and parts of Berlin
Paracelsus Medical University List of all GP practices of the province of Salzburg; list of all GP practices providing care for
patients with statutory public health insurance in the region of South Eastern Bavaria
South Tyrolian Academy of General Practice Research network of primary care practices of the Scuola Veneta di Medicina Generale (SVeMG)
University of Manchester Primary Care Research Network East of England (PCRN EoE) and others
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The PRIMA-eDS tool supports GPs to reconsider,
modify or stop the use of certain drugs in older pa-
tients with polypharmacy. Recommendations provided
by the tool do not replace careful clinical consider-
ation by physicians, nor clinical guidelines, but aim at
supporting clinical decisions.
After entering diagnoses, current medication includ-
ing drugs that have not been prescribed by the GP,
and other patient data (current symptoms, biometric
measurements and laboratory values), the GP will receive
an on-screen “Comprehensive Medication Review” report,
generated by the PRIMA-eDS tool and detailing all the
relevant prescribing recommendations. The patient’s list
of medications can then be reviewed and revised accord-
ingly by the GP in a shared decision-making process with
the patient. A record will be made of which recommenda-
tions were adopted. GPs will be explicitly instructed that
any decision to continue or discontinue a drug according
to or against the advice of the PRIMA-eDS tool remains
at the discretion of the GP and the patient. All interven-
tion GPs will be trained to use the PRIMA-eDS tool.
Training options will include personal training, group
training, webinars and a handbook.
Before the start of the trial, the tool has been evaluated
in a feasibility study which has been presented at the 16th
annual meeting of the German Network for Evidence-
based Medicine [33]. The tool as a whole has not yet been
tested for validity or reliability, but substantial work has
demonstrated the feasibility and applicability of the vari-
ous components of the tool. The use of clinical decision
support (CDS) for promoting appropriate, safe, and cost-
effective drug use has become common as an inbuilt fea-
ture of advanced electronic health record (EHR) systems
[34]. CDS can also be implemented as an externally of-
fered service that is integrated with an EHR [35]. The
EBMeDS CDS system (www.ebmeds.org) is a service de-
veloped by Duodecim Medical Publications Ltd. since
2003. An early version of EBMeDS containing a variety of
decision support rules was evaluated in a randomized con-
trolled trial [36]. Databases on drug-drug interactions and
renal dosing developed by Medbase Ltd. have been in-
cluded in EBMeDS. The design and usability of these data-
bases have been described [31, 37, 38], and their impact
evaluated [39, 40]. Because of its modular design, compre-
hensiveness and easy integration with EHRs and case-
report forms, EBMeDS was selected as the platform for
developing the PRIMA-eDS tool. All components of the
tool are regularly updated during the trial by the corre-
sponding provider and by the PRIMA-eDS consortium.
Control
GPs in the control group will be asked to record the
medication and other data of the participating patients
at the same time points as the intervention group.
Control group GPs will provide their patients with the
care they would normally receive (usual care), including
adhering to any relevant current guidelines, some of
which may be country-specific, but without the help or
recommendations from the PRIMA-eDS tool which will
not be available to them.
Documentation and monitoring
Baseline-examination
Shortly after consent is obtained, the GPs will assess
the following parameters and record all data in each
patient’s electronic case report form (eCRF):
 Age, sex, height, weight, systolic and diastolic blood
pressure
 All drugs with a systemic effect
 All diagnoses
 Current symptoms (within last month)
 Falls within the last 3 months requiring medical
attention
 Creatinine, blood glucose, alanine aminotransferase
(ALT), hemoglobin A1c (HbA1c), platelet count,
international normalized ratio (INR), cholesterol,
low-density lipoprotein (LDL)-cholesterol, high-density
lipoprotein (HDL)-cholesterol, triglycerides, potassium,
sodium. With the exception of creatinine level, GPs
should not initiate additional laboratory examinations
solely for the study due to ethical reasons and to avoid
contamination in this pragmatic trial. They should
rather enter the latest values available in the health
record and include the date of the measurement. If
the tool requires a laboratory value for a recommen-
dation, it provides this information to the GP. The GP
can then decide whether to perform the laboratory
examination or not
 Smoking behavior
 Medical procedures (e.g., stenting, heart valve
replacement)
 Frailty according to the Clinical Frailty Scale [41]
 Quality of life questionnaire (SF-12v2) to be filled
out by the patient [42]. This will be administered by
the GP to the patient on paper. The filled out forms
will then be sent to the study centre for electronic
data entry
Follow-up
At follow-up visits (at 8 and 16 months) and final
examination (24 months) the same data will be re-
corded again for all patients. One exception is the
quality of life questionnaire (SF-12v2), which will be
collected at 8 and 24 months only. GPs in the inter-
vention group will conduct further medication reviews
using the PRIMA-eDS tool for their participating pa-
tients, and make the medication changes they think
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are appropriate, at each follow-up and final visit. Control
group GPs will continue to provide usual care to their
patients.
Monitoring
Monitoring is performed according to a prespecified
monitoring charter. Independent monitors selected by
the corresponding study centers will conduct all moni-
toring. Inclusion and exclusion criteria will be checked
electronically. The monitors will control whether the in-
formed consent forms of all participants are correctly
filled out and signed. All other data will be monitored at
each follow-up visit in a random sample of 10 % of the
GPs. On-site visits are performed at T0 and T3. Moni-
tors will compare the entries of all study patient records
to the entries in the eCRF regarding age, sex and medi-
cation. In a random sample of three patients, monitors
will check the eCRF entries of the medication plus
doses, diagnoses, falls, and laboratory results as well as
height and weight, and compare these data to the patient
record. Additionally at T3, monitors will check all re-
ported and not reported non-elective hospital admis-
sions as well as adherence to protocol visits with the
practice record. At T1 and T2 monitors will check this
via phone verification. Furthermore, at T1 to T3, moni-
tors will monitor 100 % of the reported dropouts via
phone verification, and in a random sample of 10 % of
the practices they will check the reported hospital ad-
missions and deaths of all patients of the practice.
For safety purposes, the PRIMA-eDS consortium will
appoint a Safety and Data Monitoring Committee
(SDMC) consisting of three experienced researchers, in-
cluding one clinical trial statistician. The committee is
independent from the investigators and will review the
accumulated trial data. They will perform interim ana-
lyses regarding the primary endpoints 4 months after
the follow-up visits exclusively for safety reasons and
without disclosure of the randomization. Additionally,
ADEs will be monitored regularly. The results will be
available only to the SDMC. The SDMC will report any
recommendation on necessary trial modifications or a
trial abort to the principal investigator and the coordin-
ating monitors. The SDMC will recommend termination
of the trial if clinically relevant safety concerns arise in
either the control or the intervention group. No explicit
stopping rules have been developed.
Primary outcome
The primary outcome is a composite endpoint of first
non-elective hospital admission or death during the ob-
servation period measured as a binary outcome. This
avoids issues of a potential trade-off between these two
forms of event and also allows all patients to be included
in the primary analysis. Primary outcome measures are
recorded by the GPs when they occur or at follow-up
visits every 8 months.
Secondary outcome
Secondary endpoints are all cause mortality, non-
elective hospital admission (number of episodes and
duration), falls (number and severity), fractures, qual-
ity of life (SF-12v2), the number and types of drugs
(total number, number discontinued, number not dis-
continued despite the recommendation to discontinue,
number re-administered for symptom control), ad-
verse event rate, and medication costs over the obser-
vation period.
Potential harms and patient safety
We do not expect any specific complications or harms
for patients because only non-evidence-based medica-
tions will be discontinued. However, there is a slight
possibility that the discontinuation of a drug might lead
to reappearance or development of new symptoms. In
this case, the medication can be restarted at any time at
the discretion of the GP. The PRIMA-eDS tool only pro-
vides recommendations based on current best evidence.
The decision about the medication always remains with
the GP in agreement with the patient. Nevertheless, we
monitor potential harms. GPs are required to report ser-
ious adverse events in the eCRF as soon as they get no-
tice of the event, and all adverse events at the scheduled
study visits. They are asked to judge whether the adverse
event is associated with the intervention. All serious ad-
verse events will be reported to the SDMC for final ana-
lysis and judgment.
Data management and sample size calculation
Sample size calculation is based on binary analysis of the
primary endpoint (non-elective hospital admission or
death within 2 years). The study sets out to prove super-
iority regarding the primary endpoint. Garfinkel observed
an 18 % absolute risk reduction achieved by prudent re-
duction of polypharmacy in a non-randomized controlled
trial (from 30 % in the control group to 12 % in the inter-
vention group regarding the annual referral rate to acute
care facilities) [23]. This corresponds to a relative risk re-
duction of 60 % regarding this endpoint.
However, considerably smaller reductions than this
still represent substantial clinical and economic benefits;
therefore, this study is powered to detect a relative risk
reduction of 20 %. We expect to recruit healthier pa-
tients than Garfinkel and will use non-elective hospital
admission (yes/no) instead of referral rate, because it
seems less susceptible to bias. In addition, our primary
outcome will combine mortality with hospital admission,
since there may be trade-off between these. We have
been unable to find empirical data on which to estimate
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the rate of admission and mortality for our population,
but in England in 2010 there was an average of approxi-
mately one completed consultant episode for every per-
son in the population aged 75 years or older [43]. The
primary outcome of dropouts is coded as an ‘event’ in
both groups. Therefore, we consider a low estimate to
be half the rate observed by Garfinkel [23]: an annual
admission and mortality rate of 15 % of control patients;
or 30 % in 2 years. Calculations show that in the event
of the actual rate being higher than this, the sample size
given below is conservative (ie., larger, rather than smaller,
than requirement).
A relative risk reduction of 20 % in the intervention
group implies a 2-year event rate of 24 % for that group.
The sample size is calculated according to Hayes et al.
[44] for a power of 80 % (1-β = 0.8), α =5 %, and an as-
sumed intra-cluster correlation coefficient (for similarity
in outcomes between patients within GP practices) of no
more than 0.01 (derived from an earlier cluster-randomized
trial involving GP practices as clusters [45]). Dropouts in
both groups will be considered as treatment failures. Fur-
ther assuming attrition rates of 10 % of patients and 10 %
of GP practices over the period of the study, sample sizes
required at recruitment are 3542 patients (1771 per arm)
across 322 GP practices at a mean of 11 patients per GP
practice (Poisson random variation in patient numbers
per GP practice is assumed). To operate a practicable
number of GP practices and patients per country we are
aiming at 325 GP practices (65 per study center) recruit-
ing 3575 patients (11 patients per GP practice). See
Additional file 1: Figure S1.
We will record all data in the PRIMA-eDS eCRF and
store them in a XML-database in a secure central server
provided by Avain technologies (http://www.avaintec.com/?
lang=en). To monitor data quality, we will transfer data to
the Department of Medical Informatics, Biometry and
Epidemiology, Ruhr University, Bochum, Germany,
every week throughout the trial. Statistical analyses
will only be carried out after the end of the trial, with
no interim analysis planned. Upon completion of data
collection, Avain technologies will provide a final file
for statistical analysis.
Statistical analysis
Statistical analyses are elaborated in a prespecified statis-
tical analysis plan. The binary primary outcome will be
analyzed following intention-to-treat principles; second-
ary outcomes per protocol. A suitable generalized mixed
model will be used to account for cluster randomization.
Additionally, the study center as fixed factor is included
to avoid confounding through stratified randomization.
A two-sided α of 5 % will be used throughout.
The intervention could result in mortality rates differing
between the two trial arms, which could bias analyses of
other outcomes if simple exclusion were to be applied. If
we find evidence for differential mortality, analysis of sec-
ondary outcomes will employ appropriate adjustment
methods [46].
Besides a per protocol analysis of the primary out-
come, further sensitivity analyses will be undertaken to
assess the stability of the results to the model specifica-
tion, including time-to-event and counts of events ana-
lyses as well as patient and GP practice covariates
found to be unbalanced across the two trial arms. Ran-
dom imputation methods will be used, to investigate
the sensitivity of the chosen method for replacement of
missing values for dropouts in the primary endpoint.
Dissemination policy
All results of the trial will be published according to
a dissemination plan submitted to the EU with the
submission of the proposal. There are no publication
restrictions. Authorship eligibility guidelines will be
followed. Use of professional writers is not intended.
The full protocol, the dataset and the statistical code
can be made available upon request.
Discussion
Current knowledge about optimal drug treatment in
older patients with multiple chronic conditions is very
limited and the PRIMA-eDS trial can potentially make a
substantial contribution in this area. We are confronted
with increasing evidence that current prescribing prac-
tices, which are highly conducive of polypharmacy in the
treatment of multiple chronic diseases, do not achieve
the same benefits as are observed in younger people
with single diseases and may in fact be quite detrimental
to the health of older people with multimorbidity [10].
Very few existing studies have explicitly investigated
drug treatments in older patients, and where they have
done, have tended to focus on otherwise rather healthy
patients. In contrast, the PRIMA-eDS trial will purposely
sample and research an older-age population with mul-
tiple chronic conditions and many prescribed medicines,
and will evaluate whether the polypharmacy and in-
appropriate prescribing burden can be safety reduced
and health outcomes consequently improved within a
routine primary care context.
Our systematic reviews of the literature on drug
benefits and risks (conducted in the context of the
development of the PRIMA-eDS tool) will gather the
available evidence and evaluate it critically regarding
its applicability to an older population with multi-
morbidity [30]. We envisage that this will kick-start a
process of continuous development of new guidelines spe-
cifically addressing drug treatments in the context of
multimorbidity.
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Limitations of the study
We have explicitly decided to not include any recom-
mendations in the PRIMA-eDS tool for starting patients
on additional drugs, and this may be considered a weak-
ness of our study. Our main objective is to demonstrate
that the discontinuation of inappropriate drugs can
improve patient outcomes. A combined intervention to
stop inappropriate and start other (more appropriate)
medications would impede us from differentiating out
the effect of drug discontinuation.
Furthermore, access to medical records differs by
country. Italy and the UK are characterized by a primary
care centred health care system, with all medication data
and diagnoses available to the GP. In these two countries
we expect data from the electronic health records of the
GPs to be largely complete. This is not the case in Germany
or Austria where patients have direct access to specialists,
and not all medication prescribed by a specialist will be
known to the GP. We are asking GPs to address medication
prescribed by specialists at the study visits to assure
completeness of data. Nonetheless, patientsʼ data in these
countries carry a risk of being incomplete which might be
considered a limitation of our study. However, the problem
of incomplete medication data equally affects the interven-
tion and the control group. We therefore believe that
due to randomization being stratified by study centre,
incomplete medication data will not bias our study results.
Trial status
Recruitment started in January 2015 and is expected to
be completed by 30 September, 2015. The last follow-up
visit will be scheduled 2 years after the last patient has
been consented into the study.
Additional file
Additional file 1: Figure S1. Recruitment of 325 practices and 3575
patients for the PRIMA-eDS* trial. Figure describing the flow of recruitment
for the PRIMA-eDS trial. (JPG 117 kb)
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